Although the safety and efficacy of autologous EPC/CD34 + cell therapy have been extensively investigated in the context of ischemic heart disease [22, 23, 27–30], the use of this novel strategy for the management of patients after IS has been infrequently reported [24, 31, 32], indicating that considerable scientific research is still needed. This evidence concerns the gene CD34 and coronary artery disorder.